title: Sorafenib-induced erythema multiforme.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: MacGregor
authors.forename: David N
authors.initials: DN
authors.lastname: Silvers
authors.forename: Marc E
authors.initials: ME
authors.lastname: Grossman
authors.forename: William H
authors.initials: WH
authors.lastname: Sherman
mesh_terms: D000284:Administration, Oral; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004892:Erythema Multiforme / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D018328:Melanoma, Amelanotic / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib